Glatiramer acetate 

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression^[1][2][3].

Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels^[3].
In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(C₉H₁₁NO₃.C₆H₁₄N₂O₂.C₅H₉NO₄.C₃H₇NO₂)x.xC₂H₄O₂

147245-92-9

Solid

Off-white to light yellow

OC(CC[C@H](N)C(O)=O)=O.OC([C@@H](N)CC1=CC=C(O)C=C1)=O.OC([C@@H](N)C)=O.NCCCC[C@H](N)C(O)=O.O=C(C)O.[x].[x].[x].[x].[x]

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432.  [Content Brief]

  [2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598.  [Content Brief]

  [3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.  [Content Brief]

  [4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A  [Content Brief]